JP2024500858A5 - - Google Patents
Info
- Publication number
- JP2024500858A5 JP2024500858A5 JP2023537689A JP2023537689A JP2024500858A5 JP 2024500858 A5 JP2024500858 A5 JP 2024500858A5 JP 2023537689 A JP2023537689 A JP 2023537689A JP 2023537689 A JP2023537689 A JP 2023537689A JP 2024500858 A5 JP2024500858 A5 JP 2024500858A5
- Authority
- JP
- Japan
- Prior art keywords
- chr6
- hla
- cells
- manipulated
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130095P | 2020-12-23 | 2020-12-23 | |
| US63/130,095 | 2020-12-23 | ||
| US202163250996P | 2021-09-30 | 2021-09-30 | |
| US63/250,996 | 2021-09-30 | ||
| US202163254970P | 2021-10-12 | 2021-10-12 | |
| US63/254,970 | 2021-10-12 | ||
| US202163288492P | 2021-12-10 | 2021-12-10 | |
| US63/288,492 | 2021-12-10 | ||
| PCT/US2021/064930 WO2022140586A2 (en) | 2020-12-23 | 2021-12-22 | Compositions and methods for reducing hla-a in a cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500858A JP2024500858A (ja) | 2024-01-10 |
| JP2024500858A5 true JP2024500858A5 (https=) | 2025-07-08 |
Family
ID=81212453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537689A Pending JP2024500858A (ja) | 2020-12-23 | 2021-12-22 | 細胞中のｈｌａ－ａを低減するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240024478A1 (https=) |
| EP (1) | EP4267724A2 (https=) |
| JP (1) | JP2024500858A (https=) |
| KR (1) | KR20230124664A (https=) |
| AU (1) | AU2021409732A1 (https=) |
| CA (1) | CA3206284A1 (https=) |
| CL (2) | CL2023001860A1 (https=) |
| CO (1) | CO2023009612A2 (https=) |
| CR (1) | CR20230320A (https=) |
| IL (1) | IL303971A (https=) |
| MX (1) | MX2023007466A (https=) |
| TW (1) | TW202239959A (https=) |
| WO (1) | WO2022140586A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022331424A1 (en) * | 2021-08-16 | 2024-02-22 | Beam Therapeutics Inc. | Persistent allogeneic modified immune cells and methods of use thereof |
| IL320066A (en) * | 2022-10-05 | 2025-06-01 | Garuda Therapeutics Inc | Immunocompatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
| IL326191A (en) | 2023-08-14 | 2026-03-01 | Intellia Therapeutics Inc | Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| JPH10500310A (ja) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ |
| EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| KR20200138445A (ko) * | 2014-04-24 | 2020-12-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| SG10202106058WA (en) | 2016-12-08 | 2021-07-29 | Intellia Therapeutics Inc | Modified guide rnas |
| EP4029943A1 (en) | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| WO2019160077A1 (ja) * | 2018-02-16 | 2019-08-22 | 国立大学法人京都大学 | 低抗原性細胞の製造方法 |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| AU2019282824C1 (en) | 2018-06-08 | 2026-04-23 | Intellia Therapeutics, Inc. | Modified guide RNAS for gene editing |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| IL282267B2 (en) | 2018-10-15 | 2026-03-01 | Univ Massachusetts | Programmed DNA editing by chimeric deaminase-nme2cas9 proteins |
| CN113227374A (zh) | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| WO2020146290A1 (en) * | 2019-01-07 | 2020-07-16 | Crisp-Hr Therapeutics, Inc. | A non-toxic cas9 enzyme and application thereof |
| CA3181340A1 (en) * | 2020-04-28 | 2021-11-04 | Intellia Therapeutics, Inc. | Methods of in vitro cell delivery |
-
2021
- 2021-12-22 CR CR20230320A patent/CR20230320A/es unknown
- 2021-12-22 MX MX2023007466A patent/MX2023007466A/es unknown
- 2021-12-22 AU AU2021409732A patent/AU2021409732A1/en active Pending
- 2021-12-22 TW TW110148217A patent/TW202239959A/zh unknown
- 2021-12-22 IL IL303971A patent/IL303971A/en unknown
- 2021-12-22 WO PCT/US2021/064930 patent/WO2022140586A2/en not_active Ceased
- 2021-12-22 CA CA3206284A patent/CA3206284A1/en active Pending
- 2021-12-22 KR KR1020237024853A patent/KR20230124664A/ko active Pending
- 2021-12-22 EP EP21856911.9A patent/EP4267724A2/en active Pending
- 2021-12-22 JP JP2023537689A patent/JP2024500858A/ja active Pending
-
2023
- 2023-06-20 CL CL2023001860A patent/CL2023001860A1/es unknown
- 2023-06-22 US US18/339,665 patent/US20240024478A1/en active Pending
- 2023-07-19 CO CONC2023/0009612A patent/CO2023009612A2/es unknown
- 2023-10-17 CL CL2023003086A patent/CL2023003086A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024500858A5 (https=) | ||
| US20240252543A1 (en) | Crispr/cas-related methods and compositions for improving transplantation | |
| US11590171B2 (en) | Targeted replacement of endogenous T cell receptors | |
| JP7590015B2 (ja) | 低抗原性細胞の製造方法 | |
| JP2024501246A5 (https=) | ||
| JP2021518161A5 (https=) | ||
| JP2021518160A5 (https=) | ||
| US11761004B2 (en) | Safe harbor loci | |
| EP4232049A1 (en) | Safe harbor loci | |
| US20240307444A1 (en) | Methods and compositions for improved immunotherapies | |
| EP4479067A2 (en) | Dna constructs for improved t cell immunotherapy | |
| KR20200129959A (ko) | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 | |
| US20250195572A1 (en) | Methods and compositions comprising fusion proteins for improved immunotherapies | |
| US20250270546A1 (en) | Guide rnas and uses thereof | |
| Babu et al. | Cancer gene therapies progress in pre and postgenomics era | |
| EP4384615A2 (en) | Engineering cells for cell-based therapies, and associated compositions and methods | |
| Aznauryan | Identification and validation of novel human genomic safe harbor sites | |
| WO2026019837A1 (en) | Compositions and methods for overcoming t-cell exhaustion | |
| CA2986262C (en) | Crispr/cas-related methods and compositions for improving transplantation | |
| Bouazzaoui | Chimeric Antigen Receptor (CAR)-T Cell Therapy: State of the Edge and the Recent Strategies Using CRISPR and mRNA | |
| Khandelwal et al. | Alemtuzumab for Steroid Refractory Acute Graft Versus Host Disease in Pediatric Patients: A Retrospective Review of 12 Patients Reveals a Response Rate of 83% |